Dasatinib

目录号:S1021 别名: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。

规格 价格 库存 购买数量  
RMB 1142.64 现货
RMB 1224.97 现货
RMB 3039.93 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献65篇:

客户使用该产品的13个实验数据:

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述 Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。
靶点
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型(除了T315I)的Ba/F3增殖时,Dasatinib效果比Imatinib高很多。与Imatinib相比,Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型(除了T315I)。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域,且抑制自磷酸化和底物磷酸化,这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时,效果比Imatinib高325倍多。[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。 有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖,而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。[2] Dasatinib 处理一系列甲状腺癌细胞,抑制Src信号, 降低生长速度,使细胞周期停滞,且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天,抑制50%细胞生长,然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP,SW1736 和 K1 细胞,导致G1期细胞提高9-22%,而S期细胞百分数则降低7-18%。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XOPFczKGh? NVfkepY1TE2VTx?= Mli0TWM2OD1yLkCwNFA4KM7:TR?= MkGzNVc6PTZyOEC=
K562 MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3zc4lvPzJiaB?= MWDEUXNQ NGLWemdKSzVyPUCuNFAyKM7:TR?= NWHVRpFiOTd7NU[wPFA>
M07e MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXyXms4OiCq Mnf4SG1UVw>? NFHtOYxKSzVyPUCuNFAyOiEQvF2= Mo[yNVc6PTZyOEC=
ALL3 MV3DfZRwfG:6aXOgRZN{[Xl? NUS0THppOC5zzszN M3jKTFczKGh? MU\EUXNQ MXXJR|UxRTBwMECwOEDPxE1? M1PLWlE6QDh7NUSw
CML MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqyNEBucW5? NEfneItFVVOR NHXPV|NKSzVyPUCuNFAyKM7:TR?= M4XxclE6OjF7MEG2
BA/F3 NGrMWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHYdHM4OiCq MkfpSG1UVw>? MVzJR|UxRTZwNUi5JO69VQ>? M13XN|I{ODh6NkS0
BA/F3 M{jpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\qO|IhcA>? MlzhSG1UVw>? NV;HSZZTUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0> NGLyfXkzOzB6OE[0OC=>
BA/F3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfHO|IhcA>? NGPhenlFVVOR NXPVWIhRUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= NGTIdFYzOzB6OE[0OC=>
BA/F3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO4SIc4OiCq Mmn3SG1UVw>? MmDwTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP MnK0NlMxQDh4NES=
BA/F3 M13LXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnmyO|IhcA>? NVnYPYpLTE2VTx?= MoPTTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1? NIj1boUzOzNyMUewNy=>
BA/F3 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm3OYdJPzJiaB?= NIC3Rm9FVVOR NX;6e4tjUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUK1OWshdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOzMQvF2= NInvR2szOzNyMUewNy=>
BA/F3 NUnjeWJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXu3NkBp NEe4[XpFVVOR NELnN2RKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= M4jPWFI{OzBzN{Cz
BA/F3 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[3NkBp MU\EUXNQ MUjJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO NXTKSIc4OjN|MEG3NFM>
BA/F3 M4m2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGezWYs4OiCq NYXNWGxRTE2VTx?= M1HZcWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{|ryP M4joflI{OzBzN{Cz
BA/F3 M3;1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrNWpU6PzJiaB?= MWnEUXNQ MmXSTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCEQ2KtRWJNKGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjByMUpOwG0> NXr3N|RvOjN|MEG3NFM>
BA/F3 NUTVU3FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7PO|IhcA>? NEnIVWJFVVOR Mmm2TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1? MknENlM{ODF5MEO=
BA/F3 M3T2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXlO|IhcA>? NH;Sb5JFVVOR NWLjTnFlUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiVEOxOWkhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCzMlbPxE1? NWTvPYtbOjN|MEG3NFM>
BA/F3 NHHBXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUS3NkBp M3jEfmROW09? MmjuTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP NILleIQzOzNyMUewNy=>
T cell M1jPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrPcpc4OiCq Ml;3SG1UVw>? MXrJcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=> NX7OVohPOTdzNUS1NVI>
WiDr NUXhVJJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7nXoVFPzJiaB?= NH3ZW4xFVVOR NVzmTFdSUUN3ME2wMlA2OiEQvF2= NILPeFMyPTZzNUWxNi=>
PC3 NWmwb2xsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfxUmg4PzJiaB?= NFmxbGpFVVOR NXrGXpg1UUN3ME2wMlAxQTRizszN NF:3XHQyPTZzNUWxNi=>
MDA-MB-231 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\UO|IhcA>? NGnPflhFVVOR NF7ieHBKSzVyPUCuNFEzKM7:TR?= MYGxOVYyPTVzMh?=
Hs578T NV;TcJNJS3m2b4TvfIlkKEG|c3H5 NIfPbIM4OiCq M3jUW2ROW09? MorFS2k2OD1yLkCzJO69VQ>? NFLkcZQzPDBzNUOyOy=>
HMEC MUDDfZRwfG:6aXOgRZN{[Xl? M3T2elczKGh? MUTEUXNQ MoPZS2k2OD1zLkig{txO NUCzRYZ[OjRyMUWzNlc>
DU145 NVTHUGFoS3m2b4TvfIlkKEG|c3H5 MoDPO|IhcA>? MW\EUXNQ NUKyfYVvT0l3ME2wMlE3KM7:TR?= M1HhPFI1ODF3M{K3
U251 M4P0[2N6fG:2b4jpZ{BCe3OjeR?= NH\obXQ4OiCq MljpSG1UVw>? NVn5OWF{T0l3ME2yMlgyKM7:TR?= MUiyOFAyPTN{Nx?=
NCI60 MXrDfZRwfG:6aXOgRZN{[Xl? NVPm[HlWPzJiaB?= MnnGSG1UVw>? M2\KbGdKPTB;NT63JO69VQ>? NF7zXWYzPDBzNUOyOy=>
MALME-3M MV;DfZRwfG:6aXOgRZN{[Xl? M4SzUlczKGh? NIXBXVhFVVOR NH7DcGtIUTVyPU[uOlEh|ryP M4fKdFI1ODF3M{K3
KM12 NYrUeI9pS3m2b4TvfIlkKEG|c3H5 MYq3NkBp MlXVSG1UVw>? NXLGXY5sT0l3ME23MlQ1KM7:TR?= NILxWmszPDBzNUOyOy=>
SW620 NEWzXIVEgXSxdH;4bYMhSXO|YYm= M2nzZVczKGh? MoLMSG1UVw>? NWfUfppxT0l3ME24MlQ{KM7:TR?= MojuNlQxOTV|Mke=
RXF 393NL MmCzR5l1d3SxeHnjJGF{e2G7 M4jUb|Qh\GG7cx?= MmTsSG1UVw>? MVLJR|UxRTBwMEKxO{DPxE1? NX;1OW9MOjN{NUOwO|Q>
LXFA 983L MYjDfZRwfG:6aXOgRZN{[Xl? MVq0JIRigXN? MVjEUXNQ NUfqOIw3UUN3ME2wMlA2PjVizszN NYXZcZZVOjN{NUOwO|Q>
PRXF DU145 NHXURZNEgXSxdH;4bYMhSXO|YYm= Ml7jOEBl[Xm| NXnXPGhUTE2VTx?= Mn\pTWM2OD1yLkC2NlMh|ryP M2exWFI{OjV|MEe0
PAXF 1657L NXjvc2Z1S3m2b4TvfIlkKEG|c3H5 MlXYOEBl[Xm| MXnEUXNQ NYLGTXgyUUN3ME2wMlEzOSEQvF2= NVW2NWZoOjN{NUOwO|Q>
CXF 1103L MXTDfZRwfG:6aXOgRZN{[Xl? MorIOEBl[Xm| MkL4SG1UVw>? NHLvZZlKSzVyPUSuN|Yh|ryP M1z2[|I{OjV|MEe0
GXF251L MVjDfZRwfG:6aXOgRZN{[Xl? MkHmOEBl[Xm| MnXzSG1UVw>? M174TmlEPTB;Mj6yOUDPxE1? MojQNlMzPTNyN{S=
NCI-H23 NEHPb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T1fVczKGh? NV7ORoZxTE2VTx?= NY[1Zm9uUUN3ME2yMlI4KM7:TR?= M2PMS|I{PTJzMEKw
HCT116 Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf4fnIzPzJiaB?= M2HwNmROW09? NVe0S|JRUUN3ME2yMlMh|ryP NH24VFczOzV{MUCyNC=>
MCF7 M3qzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXG3NkBp M4THcmROW09? M{X1U2lEPTB;Mj61O{DPxE1? NXXONlhJOjN3MkGwNlA>
NCI-H460 Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVS3NkBp MlzFSG1UVw>? NGXGdZhKSzVyPUiuPVkh|ryP NWKxOY9iOjN3MkGwNlA>
DLD1 M4fOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLIO|IhcA>? M1LjRmROW09? NYXWfXJyUUN3ME20MlYh|ryP M3OwSlI{PTZ5OU[w
NCI-H661 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13SflczKGh? NVe0fFhKTE2VTx?= Mkj4TWM2OD15Lkig{txO M17qRlI{PTZ5OU[w
A549 NVq2fJlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVq3NkBp NVLrVHA1TE2VTx?= MV3JR|UxRThwMjFOwG0> M4i0TVI{PTZ5OU[w
U937 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13xRVczKGh? NYn5NVlUTE2VTx?= MYHJR|UxRTF{LkKg{txO Ml3DNlM2Pjd7NkC=
HEK293 MkDUSpVv[3Srb36gRZN{[Xl? NHTBfpoyOMLizszN MVnEUXNQ NYrhPVJ2UW6mdXPld{BjcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIZ2dGxvbHXu[5RpKEircz30ZYdo\WRiTYn0NUBscW6jc3Wg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNkROwG0> NV7FdnlbOjJ5N{C2NVA>
HUVEC NWfZR|lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:wMlE2yqEQvF2= Mk\DO|IhcA>? MX3EUXNQ NWLaWWQ{UW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVO NV7YWnAyOjJ6NUO5PVM>
HUVEC MWjGeY5kfGmxbjDBd5NigQ>? MXexOeKh|ryP MnXsO|IhcA>? MVPEUXNQ MXLJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKG6ndIfvdosh\m:{bXH0bY9vKGG2IEGuPEB1dyBzNTD1US=> MXGyNlg2Ozl7Mx?=
Plasmodium falciparum MWTGeY5kfGmxbjDBd5NigQ>? MnG5NVDDqM7:TR?= MlrtNVUhdWmw NUX3PWg1TE2VTx?= NFjJXVRKdmirYnn0d{BRdGG|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR|UxKG:oIEGuNVfPxE1? M3XKNVI1PTVyM{Ow
PC3 MUHGeY5kfGmxbjDBd5NigQ>? M1y4RVAvOSEQvF2= M2nQWlUhcA>? M1ryR2ROW09? M1rzNGlvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= MVSxPVQ3Ojl5NR?=
DU145 NEfGUoVHfW6ldHnvckBCe3OjeR?= MX6wMlEh|ryP M3[1UFUhcA>? NGDzW3FFVVOR MnHpTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= M{LOdFE6PDZ{OUe1
PC3 M2HwbWtqdmG|ZTDBd5NigQ>? M3jVSVAvOSEQvF2= NHTEZ2o2KGh? M3TvVWROW09? MnL3TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?= MonCNVk1PjJ7N{W=
DU145 NETiPG1McW6jc3WgRZN{[Xl? NFzpbpQxNjFizszN MUW1JIg> M4i2TmROW09? MmDOTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N MVmxPVQ3Ojl5NR?=
PC3 MVfLbY5ie2ViQYPzZZk> M4L4W|AvOSEQvF2= NIHa[Jg2KGh? MYjEUXNQ MYfJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> Mlq5NVk1PjJ7N{W=
DU145 MnWyT4lv[XOnIFHzd4F6 MUKwMlEh|ryP M4jzXVUhcA>? NHHobWdFVVOR M4rrNmlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P NGK2e|QyQTR4Mkm3OS=>
Huh7 NUjueYRRSW62aY\pdoFtKEG|c3H5 NVTlRWZmOi53IN88US=> NHz3OIM1KGSjeYO= MX7EUXNQ NHfSTIZKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2= NFmwNpUyPzN4ME[3Oi=>
C6/36 M{Toe2FvfGm4aYLhcEBCe3OjeR?= MkLLNk42KM7:TR?= NIW1WWw1KGSjeYO= MXXEUXNQ NGPlcGRKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M|M3KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP NFLZRo0yPzN4ME[3Oi=>
U937 NF7MTGtHfW6ldHnvckBCe3OjeR?= MlLaNUDPxE1? NFe5[ngyKGh? M{\aZmROW09? NFrYSplT\WS3Y3XzJIJie2GuIGTOSoFteGijIILlcIVie2ViaX6gbJVu[W5iVUmzO{Bk\Wyucx?= NVfUTYg2OTd4OESwPVk>
U937 MVHGeY5kfGmxbjDBd5NigQ>? MUmxJO69VQ>? NED6fIoyKGh? MlnNSG1UVw>? MXzS[YR2[2W|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=> MkXoNVc3QDRyOUm=
murine mast cell NWHzVpBqTnWwY4Tpc44hSXO|YYm= MWSxJO69VQ>? MlPUNlQhcA>? NFrqTmJFVVOR M2KzRmlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP NHTSeZYyPzZ6NEC5PS=>
BV-173 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjRTWM2OD1yLkCwNFAxODFyOTFOwG0> MknQV2FPT0WU
K-562 Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\wWpVKSzVyPUCuNFAxODByMk[2JO69VQ>? MWfTRW5ITVJ?
BL-70 M2nwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfKTWM2OD1yLkCwNFAxODh{MjFOwG0> MXjTRW5ITVJ?
EM-2 NIDhbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMECwNFAyODhizszN MWjTRW5ITVJ?
LAMA-84 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMECwNFA{OjFizszN MofpV2FPT0WU
MEG-01 M4jtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPWXItKSzVyPUCuNFAxODB7ODFOwG0> NXHSXIFKW0GQR1XS
EoL-1-cell MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnmfnE6UUN3ME2wMlAxODBzM{Gg{txO MnXoV2FPT0WU
CTV-1 NH3GT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEGxV|FKSzVyPUCuNFAxODRyNDFOwG0> NGXybpNUSU6JRWK=
TE-15 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jWNmlEPTB;MD6wNFU5QSEQvF2= M3XafXNCVkeHUh?=
NOS-1 NFHQWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMEC2NVMh|ryP NEGyXFVUSU6JRWK=
D-336MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfTZ4lKSzVyPUCuNFA3OyEQvF2= MYnTRW5ITVJ?
LB1047-RCC NFjJR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojwTWM2OD1yLkCwPVg6KM7:TR?= NIi0XHNUSU6JRWK=
LB996-RCC M3;Efmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\zOZFKSzVyPUCuNFA6QTFizszN MXrTRW5ITVJ?
SW982 NWfTUGI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K1fmlEPTB;MD6wNVEyPSEQvF2= NYHzTmY2W0GQR1XS
TK10 Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPodJdKSzVyPUCuNFEyPzRizszN M2jvUXNCVkeHUh?=
A704 M1;aSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG2d4w6UUN3ME2wMlAyPDlzIN88US=> MnPnV2FPT0WU
TE-8 NVrxO3VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G5OGlEPTB;MD6wNVU4PiEQvF2= NVXKd|c3W0GQR1XS
DOHH-2 M3jueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnpXmI5UUN3ME2wMlAyPzF7IN88US=> NVjuNXFoW0GQR1XS
HOP-62 NHvO[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjVTWM2OD1yLkCxPFM1KM7:TR?= MojMV2FPT0WU
TE-12 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf2TWM2OD1yLkCxPFYyKM7:TR?= MkjuV2FPT0WU
KGN NHHmU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMEG5OFIh|ryP NXPmTJhxW0GQR1XS
NCI-H1648 Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHYTWM2OD1yLkCyNFEyKM7:TR?= M2eyOHNCVkeHUh?=
OS-RC-2 NV\6UWlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvFTWM2OD1yLkCyNFMh|ryP NXzxdG1GW0GQR1XS
GB-1 NXPP[4hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjOcVRDUUN3ME2wMlAzOTV5IN88US=> Mkm5V2FPT0WU
RXF393 NXrBZ21GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3xTWM2OD1yLkCyN|U4KM7:TR?= MU\TRW5ITVJ?
LC-2-ad NH7WU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HsUWlEPTB;MD6wNlU5PiEQvF2= MYLTRW5ITVJ?
KS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moe1TWM2OD1yLkCyO|Mh|ryP Mk\SV2FPT0WU
ETK-1 M{XRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTXdWVHUUN3ME2wMlAzQDN{IN88US=> NI\wO4hUSU6JRWK=
SW954 NI\xNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfCcZE6UUN3ME2wMlAzQTJ5IN88US=> NWLyN|ZkW0GQR1XS
Becker MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\oO|N4UUN3ME2wMlA{ODB|IN88US=> MVjTRW5ITVJ?
MZ1-PC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHqPYRiUUN3ME2wMlA{OTF7IN88US=> NYXWRmdMW0GQR1XS
ES6 M2jJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O5bGlEPTB;MD6wN|E6OyEQvF2= NVLFZ|BnW0GQR1XS
KURAMOCHI MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S0UWlEPTB;MD6wN|Q5PyEQvF2= NGfrTXBUSU6JRWK=
CGTH-W-1 NHy3WYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LtfWlEPTB;MD6wN|U1QCEQvF2= M1H5ZnNCVkeHUh?=
VA-ES-BJ MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fCRWlEPTB;MD6wN|kxOiEQvF2= NUfWb3ZIW0GQR1XS
LXF-289 MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTLTWM2OD1yLkCzPVU3KM7:TR?= MYPTRW5ITVJ?
MPP-89 M2nlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLk[5hKSzVyPUCuNFQxPDlizszN Mn\jV2FPT0WU
SW872 NH7yNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrJ[ppKSzVyPUCuNFQyPjFizszN NYjJW4xpW0GQR1XS
SNB75 NFTVVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\hZ|FKSzVyPUCuNFQ1OzVizszN M2nqWnNCVkeHUh?=
PSN1 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMES0O|Qh|ryP Mlr2V2FPT0WU
LB831-BLC M3;yU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fzTGlEPTB;MD6wOFYxQSEQvF2= NILNZW9USU6JRWK=
MFH-ino NYnYTGxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDQTYpTUUN3ME2wMlA1PzJ2IN88US=> NFPBRVNUSU6JRWK=
TGBC24TKB NX;kXItQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17KcGlEPTB;MD6wOFc3OSEQvF2= MVrTRW5ITVJ?
A388 M{DEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX2PYpIUUN3ME2wMlA2ODl3IN88US=> MWjTRW5ITVJ?
BB30-HNC M4XP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMEW0N|ch|ryP M1rSb3NCVkeHUh?=
GI-ME-N NI[1RnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHReWdKSzVyPUCuNFYyOThizszN MXHTRW5ITVJ?
TGBC1TKB MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X4WWlEPTB;MD6wOlE3PCEQvF2= NF3M[3NUSU6JRWK=
TE-10 M2LPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPueYVKSzVyPUCuNFY{PTdizszN NEHibXVUSU6JRWK=
A498 NU\3dGVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Kyb2lEPTB;MD6wO|I5PCEQvF2= MoHnV2FPT0WU
TE-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[ybG1KSzVyPUCuNFc5PThizszN NV\jdVk5W0GQR1XS
BB65-RCC M1;BNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHGTWM2OD1yLkC4NlI4KM7:TR?= MkTPV2FPT0WU
C2BBe1 Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DHXmlEPTB;MD6wPFMxQCEQvF2= NEHqephUSU6JRWK=
NCI-H747 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTPTWM2OD1yLkC4N|YzKM7:TR?= M2rvfnNCVkeHUh?=
IST-MES1 NFnJUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXnWZBEUUN3ME2wMlA5PTV{IN88US=> MmrCV2FPT0WU
KALS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jHfWlEPTB;MD6wPVQ6KM7:TR?= M3j6e3NCVkeHUh?=
GCIY MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[0cmhKSzVyPUCuNFk3PTZizszN MnzuV2FPT0WU
RL95-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMUCzPEDPxE1? MUXTRW5ITVJ?
TE-1 NHTWPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMUC1OEDPxE1? M1PmVXNCVkeHUh?=
NCI-H1355 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DnWmlEPTB;MD6xNVAzQCEQvF2= M{KxbnNCVkeHUh?=
SW962 M3u2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMUGyPVIh|ryP Mmi5V2FPT0WU
KLE NWnROmNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3mTWM2OD1yLkGxN|E4KM7:TR?= M1HtS3NCVkeHUh?=
MC116 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3TbmhKSzVyPUCuNVE1OSEQvF2= NGnBV5pUSU6JRWK=
NMC-G1 NFjiXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMUG2NFYh|ryP M3TDdnNCVkeHUh?=
KU812 MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rxNGlEPTB;MD6xNVg5OyEQvF2= MVnTRW5ITVJ?
COLO-829 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3OwUWlEPTB;MD6xNlIyOyEQvF2= MoXNV2FPT0WU
NTERA-S-cl-D1 Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwMUKyPFMh|ryP NGHG[ZFUSU6JRWK=
IST-MEL1 M3vvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPxTWM2OD1yLkGzOFUh|ryP MXvTRW5ITVJ?
MLMA MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHWO5RKSzVyPUCuNVQxOzJizszN MXTTRW5ITVJ?
LS-123 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33k[GlEPTB;MD6xOFA3PCEQvF2= Mki5V2FPT0WU
LB2518-MEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonVTWM2OD1yLkG0NVYzKM7:TR?= M2e0[3NCVkeHUh?=
NB69 NICyeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDoT45ZUUN3ME2wMlE1PDN4IN88US=> NXn1eI8{W0GQR1XS
8-MG-BA NXq1XGJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HMT2lEPTB;MD6xOVQ2QCEQvF2= M4[5c3NCVkeHUh?=
K5 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfMTWM2OD1yLkG2OFg6KM7:TR?= MULTRW5ITVJ?
KINGS-1 NFTjNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fmSGlEPTB;MD6xOlY3PiEQvF2= MX3TRW5ITVJ?
SF268 NVTueGVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFuxT3hKSzVyPUCuNVc1ODRizszN NWPtfoh3W0GQR1XS
PF-382 MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP1TWM2OD1yLkG3Olc5KM7:TR?= Mo\FV2FPT0WU
SH-4 Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H5UGlEPTB;MD6xPFQyOyEQvF2= NUfSR3ByW0GQR1XS
NALM-6 NXvJc3ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj3R2tKSzVyPUCuNVkzQTVizszN NFT0cYdUSU6JRWK=
CP66-MEL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvyflVnUUN3ME2wMlE6PTNzIN88US=> M1Lr[3NCVkeHUh?=
697 M1\uOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLBbm9KSzVyPUCuNVk6QDdizszN MmrDV2FPT0WU
CP67-MEL NHP4fYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTRZ3pKSzVyPUCuNlA1QDhizszN MXLTRW5ITVJ?
DSH1 M1TEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL4TWM2OD1yLkK0NFAyKM7:TR?= M{PscnNCVkeHUh?=
HCE-4 M4nyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMk[0N|kh|ryP MW\TRW5ITVJ?
MZ2-MEL NGLmUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\YTWM2OD1yLkK4OVM4KM7:TR?= MonoV2FPT0WU
BL-41 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrpNVhKSzVyPUCuNlkyOjNizszN NEjOWmJUSU6JRWK=
HUTU-80 NFXXd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYThVpB4UUN3ME2wMlMyPDJizszN M{\MSnNCVkeHUh?=
LOXIMVI MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rCPGlEPTB;MD6zNVUxOyEQvF2= MX7TRW5ITVJ?
no-10 M4H4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy3WYU{UUN3ME2wMlMyQTNzIN88US=> M3XWOnNCVkeHUh?=
KARPAS-422 NHHLRWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DUS2lEPTB;MD6zN|k6PyEQvF2= NF7rSmNUSU6JRWK=
SW684 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT5TWM2OD1yLkO0PVgh|ryP MkPrV2FPT0WU
SF126 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M161cmlEPTB;MD6zOVQyKM7:TR?= NFixc5dUSU6JRWK=
D-263MG M4DOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3yTWM2OD1yLkO2NlI1KM7:TR?= Mkf1V2FPT0WU
OVCAR-4 M17WeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\TW4g2UUN3ME2wMlM4PDN|IN88US=> MVXTRW5ITVJ?
BB49-HNC M33ObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLCTWM2OD1yLkO4OVk6KM7:TR?= NHvwS4RUSU6JRWK=
ONS-76 NFjOdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfST2NKSzVyPUCuOFI6PTFizszN MVzTRW5ITVJ?
MZ7-mel MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvZTIF6UUN3ME2wMlQ4QTFzIN88US=> NUnq[FloW0GQR1XS
RCC10RGB MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEmwV4lKSzVyPUCuOFkyOSEQvF2= MmrSV2FPT0WU
BOKU NFfzXotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwNEmxN|Mh|ryP M1L1ZnNCVkeHUh?=
no-11 M{frTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwNUCyNlgh|ryP MmnkV2FPT0WU
IST-SL2 MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNUCzNFIh|ryP NWnvOoJVW0GQR1XS
RKO M4XBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[xTWM2OD1yLkWyPVY3KM7:TR?= MUnTRW5ITVJ?
HT-144 NWLSb4lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTnRYJKSzVyPUCuOVM3ODlizszN NF\YT5BUSU6JRWK=
NCI-H446 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwNkK3OkDPxE1? M2HqNXNCVkeHUh?=
QIMR-WIL NUPwb3d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULY[pVYUUN3ME2wMlcxPjJ7IN88US=> M{np[nNCVkeHUh?=
MHH-PREB-1 NGDxdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHreGpKSzVyPUCuO|Q1PjlizszN NVHXS4JRW0GQR1XS
EW-16 Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;5dWlEPTB;MD63OlE4QCEQvF2= MYHTRW5ITVJ?
EW-24 M2\3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PHTmlEPTB;MD63PFE3PSEQvF2= M4e1[HNCVkeHUh?=
LB373-MEL-D NFflVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwOEK1NFgh|ryP NIDuXnZUSU6JRWK=
TE-9 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwOEe1N|Ih|ryP MYnTRW5ITVJ?
A3-KAW Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwOUi0OVIh|ryP MV\TRW5ITVJ?
A101D MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwMEOwOFMh|ryP M2nKWXNCVkeHUh?=
OCUB-M NETNRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojlTWM2OD1zLkC0OFEzKM7:TR?= NUTs[nQ3W0GQR1XS
ES4 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXkTWM2OD1zLkC1NVQ2KM7:TR?= M4\XeXNCVkeHUh?=
TE-6 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LUdGlEPTB;MT6yNVIzPiEQvF2= M2rTR3NCVkeHUh?=
D-502MG MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjR[2h7UUN3ME2xMlI{Ozd4IN88US=> M4m5VnNCVkeHUh?=
KNS-42 NYTwbY4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X5WGlEPTB;MT6yOFQyOiEQvF2= NUDBfWdoW0GQR1XS
SNU-C2B MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwM{C1PFkh|ryP NFHkS21USU6JRWK=
NCI-H1838 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDOTWM2OD1zLkOwO|M{KM7:TR?= Mn;IV2FPT0WU
NKM-1 NHLTRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi2XHZ{UUN3ME2xMlMxQDV7IN88US=> MojqV2FPT0WU
GI-1 M4TSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjB[oJKSzVyPUGuN|YzOiEQvF2= NV23V3F[W0GQR1XS
NB5 NEToTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i1dmlEPTB;MT6zPVgzPyEQvF2= MXPTRW5ITVJ?
CAS-1 NWjYT3dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PIWWlEPTB;MT60NFk6OiEQvF2= NVHoSFlqW0GQR1XS
HCE-T MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTmTWM2OD1zLkW2O|E1KM7:TR?= M1q5dXNCVkeHUh?=
SBC-1 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzhclRXUUN3ME2xMlU4QTh2IN88US=> M4H3OXNCVkeHUh?=
JiyoyeP-2003 M13pV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\GTWM2OD1zLkezOFY3KM7:TR?= NU[1WW9vW0GQR1XS
TE-5 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T0cGlEPTB;MT63PVE{QSEQvF2= MUDTRW5ITVJ?
CAN MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDXO2xpUUN3ME2xMlgzOjV{IN88US=> NEf6eFZUSU6JRWK=
SK-UT-1 M3fvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LxZmlEPTB;Mj6xOlY6OyEQvF2= M33KRXNCVkeHUh?=
JVM-2 MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PabmlEPTB;Mj6zOlI5PCEQvF2= NEnlWXdUSU6JRWK=
LB771-HNC NHzGNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXhOVNKSzVyPUKuOVc2PTFizszN NHjwcItUSU6JRWK=
NCCIT Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\6TWM2OD1{Lki2OlE3KM7:TR?= NUTRcHoyW0GQR1XS
NCI-H2126 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnWWVNxUUN3ME2yMlg4PTV{IN88US=> NFzNN|dUSU6JRWK=
Calu-6 NULaeJA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnOVYxTUUN3ME2zMlA2PzRzIN88US=> NXO5WVY2W0GQR1XS
SK-LMS-1 M3\KZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDLTWM2OD1|LkGxPFg3KM7:TR?= M2\0VnNCVkeHUh?=
ARH-77 M3\uNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XqXmlEPTB;Mz60OlkyPSEQvF2= M{PU[3NCVkeHUh?=
NB17 Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDpTWM2OD1|Lk[zPFQ4KM7:TR?= Mm\xV2FPT0WU
A253 MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;FW2lEPTB;Mz63N|I1PiEQvF2= M37qcXNCVkeHUh?=
OPM-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnLbFV1UUN3ME20MlI4Pjh3IN88US=> NWjwZZFSW0GQR1XS
MV-4-11 NHTrTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTRwM{[0OVQh|ryP MXjTRW5ITVJ?
SR M{Doc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYGzeW0xUUN3ME20MlQ6QTV2IN88US=> MonwV2FPT0WU
KG-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHuTWM2OD12Lk[wPFQ2KM7:TR?= NUDsW3hrW0GQR1XS
OCI-AML2 NV\weZU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTVwOE[xOVQh|ryP NYfRVZVQW0GQR1XS
D-247MG MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jNcmlEPTB;Nj6xNlUyQSEQvF2= MV\TRW5ITVJ?
DJM-1 NXrWVWg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTLTWM2OD14LkS4OVU5KM7:TR?= NE[3NXZUSU6JRWK=
RPMI-6666 NHe3NVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELmXXlKSzVyPUeuNlcxPjdizszN M1riXnNCVkeHUh?=
KARPAS-45 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XOXGlEPTB;Nz61NVY4OSEQvF2= M4WyVHNCVkeHUh?=
LP-1 NGnuUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXJU3JKSzVyPUeuOVQ4QDJizszN NEDaXldUSU6JRWK=
RS4-11 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrRTWM2OD15Lk[1O|g4KM7:TR?= Mn;xV2FPT0WU
DU-4475 NYfzc5psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRThwMkG2OVIh|ryP NI\S[nBUSU6JRWK=
MONO-MAC-6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS1TWM2OD16LkK3NFY3KM7:TR?= NES1W2hUSU6JRWK=
NCI-SNU-16 NXnURVNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi4XJpKSzVyPUiuOVYyOjhizszN NITibVBUSU6JRWK=
SJSA-1 MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXTTWM2OD16LkeyPFA2KM7:TR?= M1XHXnNCVkeHUh?=
MMAC-SF MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fEbmlEPTB;OD63PVMxPyEQvF2= MXfTRW5ITVJ?
SK-NEP-1 NYjGVVJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRThwOEmxOVUh|ryP MofFV2FPT0WU
J-RT3-T3-5 NFniXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTJTWM2OD16Lkm2OVI6KM7:TR?= NHWxWodUSU6JRWK=
SKM-1 MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP2WFZKSzVyPUmuNFE4OzRizszN NHy5V4pUSU6JRWK=
LB2241-RCC NH;nWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX5[pltUUN3ME25MlAzODF{IN88US=> M3jpV3NCVkeHUh?=
SIG-M5 NIXvb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTlwMEK0PVMh|ryP NXLqO5p3W0GQR1XS
EVSA-T NEjESVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTlwMke3PVMh|ryP M2ftbnNCVkeHUh?=
GT3TKB NV7lWXprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTlwM{W1OFYh|ryP MV7TRW5ITVJ?
NB6 NGrKc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q0N2lEPTB;OT65NlI2QSEQvF2= NETRNG5USU6JRWK=
EHEB NUD6PHJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke3TWM2OD1zMD6wOlU3KM7:TR?= MUHTRW5ITVJ?
HEL M4DnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFyLkS3O|Yh|ryP M{P5Z3NCVkeHUh?=
ALL-PO NYfnZnM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jQ[GlEPTB;MUCuO|k{QCEQvF2= MnLOV2FPT0WU
TGW MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\jTWM2OD1zMT6yPFI5KM7:TR?= MXvTRW5ITVJ?
BC-3 M{nadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHFTWM2OD1zMj6xNVM5KM7:TR?= M33jUXNCVkeHUh?=
IA-LM M3ryNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEmwS5ZKSzVyPUGyMlQ1PDVizszN M1TXSHNCVkeHUh?=
UACC-257 M2HBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfYTWM2OD1zMj65NVk5KM7:TR?= M4nmWHNCVkeHUh?=
KP-N-YS M1nXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF{LkmyPFMh|ryP NWjBUHA3W0GQR1XS
Raji NHLQNlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofzTWM2OD1zMz63OFk4KM7:TR?= NETqT2RUSU6JRWK=
SF539 NXv6UZBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO0UnRKSzVyPUGzMlg2PTdizszN NVnucox2W0GQR1XS
DMS-153 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF2LkCwNlgh|ryP NVrtTZk4W0GQR1XS
L-540 Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTF3LkC2O|Ih|ryP NYPYRngzW0GQR1XS
MN-60 NF3Mb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVztd5VGUUN3ME2xOU4yQTd7IN88US=> NYmyN4pMW0GQR1XS
RPMI-8866 NGXaNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LrVmlEPTB;MUeuOFQ2PCEQvF2= NUjiWJRIW0GQR1XS
NCI-H510A MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKxSllKSzVyPUG5MlM6PzNizszN NHLNbJRUSU6JRWK=
NB13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HYWGlEPTB;MUmuOFg4PyEQvF2= MYjTRW5ITVJ?
HAL-01 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF7Lke1OFMh|ryP NIPR[|ZUSU6JRWK=
NCI-H720 M1TqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL0eXdKSzVyPUKwMlI4OzNizszN NYLVZW5xW0GQR1XS
REH NHfOSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJyLk[zOVch|ryP MXvTRW5ITVJ?
KNS-81-FD MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrucnhKSzVyPUKzMlE1PiEQvF2= NICw[JRUSU6JRWK=
HC-1 NGnGblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PKNWlEPTB;MkSuOVU2OSEQvF2= NG\kRpVUSU6JRWK=
NCI-H2141 NITKXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1iwNWlEPTB;MkSuO|c2PCEQvF2= MoTLV2FPT0WU
MOLT-4 NF7jVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ4Lk[3OVMh|ryP NF7tV|FUSU6JRWK=
OMC-1 MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LwXmlEPTB;MkeuNVQzOiEQvF2= MXTTRW5ITVJ?
LC-1F M1fNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TJb2lEPTB;MkeuN|I1PSEQvF2= NEn6dZVUSU6JRWK=
NCI-H1304 M3jaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP6TWM2OD1{OD6xOlI5KM7:TR?= MUXTRW5ITVJ?
BC-1 NVviZVRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojhTWM2OD1{OD62OVEh|ryP NVnTOodZW0GQR1XS
NCI-H64 MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3YTWM2OD1{OT62NlU{KM7:TR?= MV\TRW5ITVJ?
MOLT-16 NW\xb41UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f6[WlEPTB;MkmuOlI6OiEQvF2= NFfLe|BUSU6JRWK=
U-87-MG MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC2TWM2OD1|MD63OlYh|ryP NUOyOIozW0GQR1XS
GAK NVXre|B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH2TWM2OD1|MT6yOlg3KM7:TR?= M2H0VnNCVkeHUh?=
ES8 M4DTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;XVIJKSzVyPUOyMlEzPTJizszN NF\PZphUSU6JRWK=
HCC1599 NECxWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nMTWlEPTB;M{KuN|MzPSEQvF2= MlizV2FPT0WU
EB-3 M1\yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3HUYU5UUN3ME2zOE4{OTF5IN88US=> M4DvTXNCVkeHUh?=
HCC1187 NEn5[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnUWJpLUUN3ME2zOU45ODV{IN88US=> MW\TRW5ITVJ?
SK-PN-DW MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fOb2lEPTB;M{[uNVk1OyEQvF2= NYW5bFh3W0GQR1XS
JVM-3 NHW2R|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTN5LkKzN|gh|ryP MnK1V2FPT0WU
HCC2157 NFjZdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTN5Lkm5OFYh|ryP NH;iSYZUSU6JRWK=
A4-Fuk MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPaPIlGUUN3ME2zPE4yODB7IN88US=> MXzTRW5ITVJ?
COR-L279 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTRyLkK4OVEh|ryP M2HKO3NCVkeHUh?=
DEL M3jDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTRzLkmwPFYh|ryP MVjTRW5ITVJ?
NCI-H1395 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{S4d2lEPTB;NEKuNFE3OyEQvF2= NVfmcZEyW0GQR1XS
MHH-NB-11 NIrUR|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTR|LkC4NVgh|ryP MVHTRW5ITVJ?
NCI-H2107 NIn6fnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\GTWM2OD12Mz60PFQ3KM7:TR?= NITYNphUSU6JRWK=
NEC8 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPq[FlKSzVyPUS0MlM{PiEQvF2= NIW4S4xUSU6JRWK=
COLO-684 M{\TW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTR4LkKyOVgh|ryP NVvlTJJWW0GQR1XS
LS-411N MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M375e2lEPTB;NEiuOFc1QCEQvF2= NEGzXIlUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 Dasatinib 作用于LMP2A/MYC 双转基因小鼠,可逆转脾肿大。Dasatinib 作用于TgE小鼠 抑制表达LMP2A 的骨髓B 细胞形成的菌落,且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠,与对照组相比,脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠,抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠,可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤,抑制Lyn磷酸化。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶自磷酸化分析:

使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白,ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30oC下温育1小时后,加入1 mM 钒酸钠,激活LAR磷酸酶。进行免疫印迹分析,比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶,使用磷酸化的特点抗体4G10来 确认酪氨酸残基完全去磷酸化(>95%),使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验: [1]
+ 展开
  • Cell lines: Ba/F3细胞系
  • Concentrations: 0 nM-32 nM
  • Incubation Time: 72小时
  • Method: Ba/F3 细胞系重复培养三份,然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 488.01
化学式

C22H26ClN7O2S

CAS号 302962-49-8
稳定性 powder
in solvent
别名 BMS-354825

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03041701 Recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2017 Phase 1|Phase 2
NCT02011945 Active not recruiting Chronic Myeloid Leukemia Bristol-Myers Squibb February 7 2014 Phase 1
NCT03297606 Recruiting Lymphoma Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors Canadian Cancer Trials Group|AstraZeneca|Bristol-Myers Squibb|Hoffmann-La Roche|Pfizer October 6 2017 Phase 2
NCT02750514 Recruiting Advanced Cancer Bristol-Myers Squibb May 6 2016 Phase 2
NCT02389309 Recruiting Solid Tumors M.D. Anderson Cancer Center October 5 2015 Phase 1
NCT02744768 Recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto May 31 2017 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 问题 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品

Tags: 购买Dasatinib | Dasatinib供应商 | 采购Dasatinib | Dasatinib价格 | Dasatinib生产 | 订购Dasatinib | Dasatinib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID